SCHEMBL13019686

SCHEMBL13019686

C#CCn1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.68
PRKDC P78527 3/20 0.68
CYP1A2 P05177 3/20 0.67
MAPK1 P28482 2/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
FYN P06241 10/20 0.60
LYN P07948 3/20 0.60
BLK P51451 3/20 0.60
ABL1 P00519 2/20 0.59
SRC P12931 4/20 0.57
BTK Q06187 2/20 0.57
YES1 P07947 2/20 0.57
FGR P09769 2/20 0.57
DAPK3 O43293 1/20 0.57
RIPK2 O43353 1/20 0.57
EGFR P00533 1/20 0.57
LCK P06239 1/20 0.57
HCK P08631 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29678005 0.87 PIK3CD (0.74) PIK3CDPRKDCCYP1A2MAPK1FYN
SCHEMBL13019687 0.83 CYP1A2 (0.75) PIK3CDPRKDCCYP1A2MAPK1MEN1
SCHEMBL29175926 0.81 PIK3CD (0.69) PIK3CDPRKDCCYP1A2MAPK1FYN
SCHEMBL30387431 0.81 PIK3CD (1.00) PIK3CDPRKDCABL1SRCEGFR
SCHEMBL29999094 0.81 PIK3CD (0.69) PIK3CDPRKDCCYP1A2MAPK1FYN
SCHEMBL13019926 0.80 FYN (0.70) PIK3CDPRKDCCYP1A2MAPK1MEN1
SCHEMBL13019782 0.80 CYP1A2 (1.00) PIK3CDPRKDCCYP1A2MAPK1MEN1
SCHEMBL13019685 0.80 PIK3CD (0.73) PIK3CDPRKDCCYP1A2MAPK1MEN1
SCHEMBL13019688 0.80 PIK3CD (0.68) PIK3CDPRKDCCYP1A2MAPK1MEN1
SCHEMBL13019998 0.80 FYN (0.77) PIK3CDPRKDCCYP1A2MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PIK3CD 2217/4885PRKDC 1498/4885CYP1A2 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.